Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Maxygen and Roche have agreed to terminate the agreement under which Maxygen licensed Maxy-alpha, also known as R7025, to Roche. The news follows Maxygen's announcement of September 21, 2007 that Roche had voluntarily placed a hold on the program.
Subscribe to our email newsletter
The Maxy-alpha program was fully funded by Roche, with no milestone payments expected in 2007 or 2008. As such, Maxygen expects no near-term impact on its financials as a result of the termination. Upon termination of the agreement, all rights to Maxygen’s interferon variant product candidates revert back to Maxygen.
Maxy-alpha was designed to be a next-generation alpha interferon for the treatment of hepatitis C and hepatitis B virus infections.
Russell Howard, CEO of Maxygen, said: “While we are disappointed, we recognized and had advised earlier that termination of the program was one of the likely possibilities. Tremendous potential remains in Maxygen’s portfolio and we look forward to 2008, a key year for our two lead programs, Maxy-G34 and Maxy-VII.”